Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-04-26
2011-10-11
Lundgren, Jeffrey S (Department: 1629)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S263100
Reexamination Certificate
active
08034808
ABSTRACT:
The invention concerns the use of a therapeutic composition comprising at least one pyrrolobenzodiazepine derivative combined with fludarabine for treating cancer and more particularly hematological diseases.
REFERENCES:
patent: 7511032 (2009-03-01), Liu et al.
patent: WO 00/12508 (2000-03-01), None
patent: WO 2005/105113 (2005-11-01), None
Johnson, S.A.: Purine Analogues in the management of lymphoproliferative disease. vol. 8, p. 289-296, 1996.
Jordan et al.: Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci, 57 (8-9):1229-1235, 2000, abstract only.
Gregson et al.: Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient corss-linking ability and potent cytotoxicity. J Med Chem, 44:737-748, 2001.
Johnson: Purine Analogues in the management of lymphoproliferative diseases. Clinical Oncology, 8:289-296, 1996.
Ross et al.: Fludarabine, A review of its pharmacological properties and therapeutic potential in malignancy. Drug, 45(5):737-759, 1993.
Written Opinion of the International Searching Authority (Form PCT/ISA/237) issued in International Application No. PCT/FR2005/001025.
S.J. Gregson et al., “Synthesis of a novel C2/C2′-exounsaturated pyrrolobenzodiazepine cross-linking agent with remarkable DNA binding affinity and cytotoxicity,”Chemical Communications, Journal of the Chemical Society, pp. 797-798 (1999).
G.P. Wilkinson et al., “Pharmacokinetics and intracellular pharmacological characteristics of the novel pyrrolobenzodiazepine (PDB) dimer SJG-136,”Proceedings of the 94thAmerican Association for Cancer Research Annual Meeting, vol. 44 (Abstract) p. 320 (Jul. 11-14, 2003).
M.C. Alley et al., “Efficacy evaluations of SJG-136 (NCS 694501), A novel pyrroloben-zodiazepine dimer with broad spectrum antitumor activity,”Proceedings of the 93rdAmerican Association for Cancer Research Annual Meeting, vol. 43 (Abstract) p. 63 (Apr. 6-10, 2002).
J.A. Hartley et al., “In vitro antitumor activity and in vivo DNA interstrand crosslinking by the novel pyrrolobenzodiazepine dimer SJG-136 (NSC 694501),”Proceedings of the 93rdAmerican Association for Cancer Research Annual Meeting, vol. 43 (Abstract) p. 489 (Apr. 6-10, 2002).
P.H. Clingen et al., “The role of nucleotide excision repair and homologous recombination in the sensitivity of mammalian cells to the minor groove crosslinking pyrrolo(2,1-c)(1,4)benzodiazepine dimer SJG-136 (NSC 694501),”Proceedings of the 94thAmerican Association for Cancer Research Annual Meeting, vol. 44, 2nded. p. 524 (Abstract) (Jul. 11-14, 2003).
G.P. Wilkinson et al., “Pharmacokinetics, metabolism & glutathione reactivity of SJG-136,”British Journal of Cancer, vol. 88, Supplement 1 (Abstract) p. s29 (Jul. 2-5, 2003).
A. Kamal et al., “Recent developments in the design, synthesis and structure-activity relationship studies of pyrrolo[2,1-c][1,4]benzodiazepines as DNA-interactive antitumour antibiotics,”Current Medicinal Chemistry—Anti-Cancer Agents, 2(2): 215-254 (2002).
M.J. Keating et al., “Clinical experience with fludarabine in hemato-oncology,”Hematology and Cell Therapy, Springer-Verlag, publisher, Supplement 2, No. 38, pp. S83-S91 (1996).
G.A. Goodman et al., “Pharmacological basis of therapeutics,”Goodman and Gilman's Pharmacological Basis of Therapeutics, Chapter 52: Antineoplastic Agents, Pergamon Press, publisher, p. 1415 (2001).
David E. Thurston et al. “Synthesis of DNA-Interactive Pyrrolo [2,1-c][1,4]benzodiazepines,” Chemical Reviews, vol. 94, No. 2, pp. 433-465, 1994.
Ting-Chao Chou “Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method”, Cancer Research vol. 70, pp. 440-446, 2010.
Lawrence D. Myer et al. “Optimizing Combination Chemotherapy by Controlling Drug Ratio” Molecular Inventions., vol. 7., Issue No. 4, pp. 216-223, Aug. 2007.
Robert A. Kratzke et al., “Evaluation of In Vitro Chemosensitivity Using Human Lung Cancer Cell Lines”, J. of Cellular Biochem. Suppl., vol. 24, pp. 160-164, 1996.
Dr. Pepper et al. “Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells” British Journal of Cancer, vol. 97, pp. 253-259, 2007.
Delavault Patrick
Pepper Chris
Baek Bong-Sook
Hunton & Williams LLP
Ipsen Pharma S.A.S.
Lundgren Jeffrey S
LandOfFree
Therapeutic compositions containing at least one... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic compositions containing at least one..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic compositions containing at least one... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4261819